Elanco Animal Health received approval from the Agriculture Department for Befrena, the company's antibody treatment for canine allergic and atopic dermatitis. The animal-medicine company said ...
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...
TipRanks on MSN
Elanco receives USDA approval for Befrena
Animal Health announced its latest entry into the canine dermatology space with the USDA approval of Befrena, a new anti-IL31 ...
And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...
In 2025, the most-read Healio story on skin disorders was about the impact dietary diversity during pregnancy has on the risk ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...
Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo ...
HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients.
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback